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■ SHORT COMMUNICATION ■
Introduction
Transitional cell carcinoma (TCC) of the ovary is a rare,
recently recognized, subtype of ovarian surface epi-
thelial cancer. The common symptoms of this tumor
include abdominal pain, abdominal swelling or disten-
sion and weight loss. In a study by Silva et al, focal or
diffuse TCC pattern was seen in 88 of 934 ovarian can-
cers [1]. Here, we present a case of TCC of the ovary,
managed by total abdominal hysterectomy and bilat-
eral salpingo-oophorectomy with infracolic omentec-
tomy and pelvic lymph node dissection followed by
postoperative chemotherapy.
Case Report
A 67-year-old postmenopausal woman presented with
a 2-year history of progressive enlargement of an abdo-
minal mass. She was referred from a local clinic after
she was diagnosed to have a large mass in the lower
abdomen using sonography. There were no changes in
bowel movement, urination habit and abdominal pain.
She had experienced weight loss of about 4 kg during
the 6 months prior to admission.
Physical examination showed a big pelvic mass,
which extended from the suprapubic region to the um-
bilical level. Abdominal ultrasound showed a pelvic
mass measuring 210 × 165 × 203 mm with homoge-
neous echogenicity (Figure 1A). Color Doppler study
disclosed no vascularity within the tumor. Abdominal
computed tomography (CT) showed a big homoge-
neous cyst on the left side of the middle abdomen, which 
was larger than 24 cm in maximal diameter without a
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SUMMARY
Objective: Transitional cell carcinoma (TCC) of the ovary is a rare, recently recognized, subtype of ovarian
surface epithelial cancer. We present a case of TCC of the ovary, managed by staging operation and followed
by postoperative chemotherapy with carboplatin and cyclophosphamide.
Case Report: A 67-year-old postmenopausal woman presented with a 2-year history of progressive enlargement
of an abdominal mass. Pelvic sonography and abdominal computed tomography showed a pelvic mass meas-
uring 210 × 165 × 203 mm. The serum CA-125 titer was also elevated (65.01 U/mL). A staging operation with
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node dissection was performed. After surgery, the pathologic report of the left ovarian tumor was TCC, grade
2–3, stage IA. The patient then underwent four cycles of postoperative chemotherapy with carboplatin and
cyclophosphamide. CA-125 levels declined to within the normal range after the first cycle of chemotherapy.
Conclusion: TCC of the ovary is a rare subtype of epithelial ovarian cancer. It differs from malignant Brenner
tumor by the absence of a benign or borderline Brenner component. Surgical resection is the primary therapeutic
approach, and patient outcomes after chemotherapy are better than for other types of common epithelial ovar-
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solid component. There was no evidence of abnormal 
lymphadenopathy. The liver and kidneys were unremark-
able (Figure 1B). Routine blood and biochemical test
results were all within normal ranges. Initial investiga-
tion of tumor markers before surgery showed elevated
serum CA-125 (65.01 U/mL; normal, 0–35 U/mL), but
other markers including CA-153, carcinoembryonic anti-
gen (CEA) and CA-199 were all within normal ranges.
She underwent surgery under the impression of
malignant ovarian tumor. A small amount of ascites
(about 100 mL) in the pelvic cavity was found intraop-
eratively. A huge cystic mass, measuring 30 × 20 × 20 cm,
arising from the left ovary and occupying the intra-
abdominal and pelvic cavities was noted. The cystic
surface was intact and smooth with no rupture.
After resection, the left ovarian mass was opened;
there was approximately 4,100 mL of tan-colored cystic
fluid. Grossly, several mural nodules, with the largest
one about 0.6 cm, were noted on the inner surface of the
cyst. Parasurgical frozen-section biopsy of the mural
nodules demonstrated the presence of an ovarian malig-
nancy. There was no enlargement of the paraaortic
lymph node on palpation. Therefore, surgical staging
procedures including total abdominal hysterectomy,
bilateral salpingo-oophorectomy, infracolic omentec-
tomy and pelvic lymph node dissection were performed.
The ascites was also sent for cytologic examination.
Microscopic examination showed malignant tran-
sitional epithelial lining of the left ovarian cyst. There
was no metastatic lesion and the cytology of the
ascites was also negative for malignant cells. The final
diagnosis was TCC, grade 2–3, stage IA. The tumor was
confined to the left ovary (Figure 2). Immunohisto-
chemical studies showed that the tumor was positive for
cytokeratin 7 (CK7) (Figure 3) and negative for CK20.
After recovering from surgery, the patient received
postoperative chemotherapy with carboplatin (area
under the curve, 5) and cyclophosphamide (500 mg/m2)
every 3 weeks for four cycles. The CA-125 level returned
to within the normal range after the first course of
chemotherapy. The patient is being regularly followed
up at our outpatient department and has been disease-
free for 10 months.
Discussion
TCC of the ovary is a recently recognized subtype of
ovarian surface epithelial cancer. It has been described
as a primary ovarian carcinoma in which definite urothe-
lial features are present but no benign, metaplastic and/
or proliferating Brenner tumor can be identified.
TCC of the ovary was first defined by Austin and
Norris [2]. They reported a group of patients who had
ovarian tumors presenting with histologic features sim-
ilar to those seen in a malignant Brenner tumor, but the
tumors lacked the associated benign Brenner tumor
component. Pure TCC was thus distinguished from
malignant Brenner tumor. In addition to not having a
benign Brenner tumor component, TCC lacks the promi-
nent stromal calcification [2].
The true incidence of TCC of the ovary remains
unknown. Further studies with standardized histopa-
thologic criteria for diagnosis are needed. At present,
clinical studies focusing on TCC are somewhat imprac-
tical due to the limited incidence.
Because TCC of the ovary has close morphologic
similarities to TCC of the bladder and it behaves more
aggressively than malignant Brenner tumor, Austin
and Norris concluded that ovarian TCC arises directly
from the pluripotential surface epithelium of the 
ovary and from cells with urothelial potential, rather
than from a benign or proliferative Brenner tumor 
precursor [2].
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Figure 1. (A) Transabdominal sonography shows a homogeneous pelvic cystic mass, measuring 210 × 165 × 203 mm, with no
blood flow. (B) Abdominal computed tomography shows a big homogeneous cyst in the left middle abdomen, > 24 cm in
diameter, with no solid component.
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As described in detail by Eichhorn and Young [4],
ovarian TCC typically showed undulating, diffuse, insular
and trabecular growth patterns. Cystic spaces of varying
sizes and blunt papillae were present in most cases. The
tumor cell nuclei were oblong or round, often exhibit-
ing nucleoli or longitudinal grooves. The cytoplasm was
often pale and granular, rarely clear or eosinophilic.
The common presenting symptoms of TCC of the
ovary are abdominal pain, abdominal swelling or dis-
tension, and weight loss. Occasionally, the patient
may present with uterine bleeding, back pain, bowel or
urinary symptoms. The clinical presentation is indistin-
guishable from other types of ovarian carcinoma [2,3].
In Ayhan et al’s study, there was a wide range of
age in women with ovarian TCC, from 46 to 87 years,
with a mean age of approximately 59 years [3]. The
vast majority of patients are postmenopausal. CA-125 is
clinically useful as a serum marker of tumor progression
and recurrence.
The immunophenotype of TCC of the ovary is simi-
lar to that of other surface carcinomas of the ovary, but
differs from that of TCC of the bladder [1]. Immuno-
histochemical staining for CEA is negative, which is
commonly found in benign and malignant Brenner
tumors [2,3]. In addition, ovarian TCCs are negative for
CK20, thrombomodulin (TM) and uroplakin III, which
are the antigens that are usually (CK20) or sometimes
(TM and uroplakin III) detected in bladder TCCs. Unlike
bladder TCCs, ovarian TCCs are often positive for
vimentin, CA-125 and Wilms’ tumor protein (WT1) [4].
Croft et al concluded that almost all of the ovarian
TCCs marked strongly for estrogen receptors (ERs), a
characteristic that may help to differentiate these lesions
from papillary urothelial carcinoma metastatic to the
ovary [5]. Shen et al described that overexpression of
p53 in TCC of the ovary was associated with a poor
prognosis [6]. However, Gershenson et al [7] concluded
that immunostaining for p53, epidermal growth factor
receptor, HER-2/neu, DNA ploidy, and S-phase frac-
tion did not distinguish TCC from other common
epithelial ovarian cancers. In another study, researchers
reported that overexpression of C-erbB3 was a com-
mon event in TCC of the ovary [8]. Further studies with
larger case numbers are warranted to clarify the role of
molecular profile in TCC of the ovary.
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Figure 2. (A) Ovarian transitional cell carcinoma. The characteristic microscopic feature is thick, blunt and often elongated
papillary folds with fibrovascular cores, lined by transitional-type epithelium resembling urothelium. The papillae often
appear to arise from a cyst wall with a similar lining of stratified and atypical transitional cells with microcystic changes. No
Brenner tumor component is identified (hematoxylin & eosin, 40×). (B) Cytologic atypia and mitotic activity are prominent
and corresponds to high grade urothelial carcinoma of the urinary tract (hematoxylin & eosin, 100×).
Figure 3. Immunohistochemical staining of an ovarian tran-
sitional cell carcinoma. Tumor cells are strongly positive for
cytokeratin 7.
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TCC of the ovary is reported to be sensitive to 
cisplatin-based chemotherapy and has a better prog-
nosis than other types of common epithelial tumors of
the ovary. Sweeten et al [9] suggested that TCC may
be more chemosensitive than other common epithelial
tumors in the refractory setting. The relative influences
of tumor biology and treatment strategies remain
undetermined. Gershenson et al [10] concluded that
advanced-stage ovarian TCC was significantly more
chemosensitive and associated with better prognosis
than poorly differentiated serous carcinoma. Kommoss
et al [11] also documented that patients with TCC
had better prognoses compared to patients with all
other types of ovarian carcinomas after standardized
chemotherapy. Optimal surgical resectability followed
by cisplatin-based chemotherapy might contribute to
the survival benefit [12].
In their study, Silva et al reported that the esti-
mated 5-year survival rate after surgery for 88 patients
was 37% [1], whereas for patients who received chemo-
therapy, it was 41%. Factors associated with survival
for patients who received chemotherapy were the clinical
stage, the percentage of TCC component in the primary
tumor, and the results of the second-look operation.
The predominance of TCC was a favorable prognostic
factor and patients with higher clinical stages had
poorer prognoses. The treatment strategy and outcome
of ovarian TCC in the literature are summarized in the
Table. Since our patient was diagnosed as an early
pathologic stage IA, four cycles of carboplatin plus
cyclophosphamide may be adequate after surgery.
Radiotherapy for this tumor is probably not appropri-
ate, since all five patients treated with postsurgical
radiation died of disease in < 5 years [1]. Tumor recur-
rence and lack of response to chemotherapy are often
associated with changes in the histologic appearance
of the primary neoplasm, which become predominantly
non-TCC lesions in recurrent tumors [1].
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Table. Summary of recent publications on treatment procedure and survival time
Authors Treatment procedure Cases, n Survival time
Austin & Norris [2] Surgery alone for ≥ stage II 14 None free of disease
Hollingsworth et al [12] Surgery + cisplatin–cyclophosphamide for stage III–IV 15 23.7 mo
Ayhan et al [3] Surgery + monthly cisplatin 100 mg–cyclophosphamide 4 ≥ 70 mo
1 g for 6 cycles
or
monthly melphalan for 10 cycles 1
Silva et al [1] Radiotherapy only 5 < 60 mo
Surgery + hexamethylmelamine–doxorubicin– 25 5-yr survival rate of 41%
cyclophosphamide, melphalan–cisplatin or melphalan
Present case Staging operation + carboplatin–cyclophosphamide 1 10 mo and still being
for 4 cycles followed up
